Important Update for Humacyte, Inc. Investors
Attention all investors of Humacyte, Inc. (NASDAQ: HUMA), there’s an important update regarding your investment that you should not overlook. As a nationwide firm recognized for defending investors' rights, it's crucial that we inform you of an upcoming deadline linked to a class action lawsuit.
Is This Class Action Relevant to You?
First, you may be wondering if this lawsuit affects you personally. If you are a current or past shareholder of Humacyte and purchased shares between certain dates, then yes, this is a vital development. Specifically, if you bought shares from mid-May to mid-October of the previous year, you may want to pay close attention to what unfolds.
Details of the Class Action Lawsuit
The lawsuit, initiated in the United States District Court, represents investors who hold shares of Humacyte, specifically for transactions completed between May 10, 2024, and October 17, 2024. This legal action is grounded in allegations of securities fraud related to the company's misleading statements regarding FDA approval processes for its products.
Why It Matters
This lawsuit centers around allegations that the company made false claims about the potential FDA clearance for its Acellular Tissue Engineered Vessel, particularly concerning conditions at their manufacturing facility, which could have serious implications for shareholders. Concerned investors are right to question the integrity of the company’s disclosures during this period.
Your Rights as an Investor
If you’ve experienced financial loss due to your investment in Humacyte, you might be eligible for recovery. To actively participate, consider the role of a lead plaintiff. This representative will engage on behalf of other class members. However, remember that participating in this capacity is optional; you can also remain as an absent class member without any repercussion regarding future financial recovery.
Next Steps
If you are contemplating participating, be advised that the application must be submitted no later than January 17, 2025. Taking action is critical if you wish to have your voice heard in this matter. Remember, all representation provided by Bernstein Liebhard LLP operates on a contingency fee basis, meaning you won't incur any legal fees unless a recovery is made.
Understanding Bernstein Liebhard LLP's Experience
This firm has an impressive track record of recovering over $3.5 billion for its clients, providing reassurance to potential plaintiffs. They have represented both individual investors and notable pension funds throughout numerous class action lawsuits and possess substantial expertise in this arena.
Contacting Bernstein Liebhard LLP
If you have any questions or wish to engage further regarding your potential role in this lawsuit, you can reach out to Investor Relations Manager, Peter Allocco, at (212) 951-2030. Alternatively, you can visit the firm's website or reach out via email for direct assistance.
Frequently Asked Questions
What is the deadline for participating in the class action?
The deadline to file papers is January 17, 2025.
Who can participate in the class action?
Any investor who purchased Humacyte shares between May 10, 2024, and October 17, 2024, may be eligible.
What does it mean to be a lead plaintiff?
A lead plaintiff represents other affected shareholders in the lawsuit and plays a significant role in the litigation process.
Are there any fees involved in joining the lawsuit?
No, there are no upfront legal fees. Representation occurs on a contingency fee basis, meaning fees apply only if you recover funds.
How can I get more information about the lawsuit?
You can contact Bernstein Liebhard LLP directly or visit their website for comprehensive details about your options.
